Skip to main content
OpenTrials
Completed

NCT Number: NCT02135562

Protein-Sparing Modified Fast Intervention for Weight Loss in Obese Endometrial Cancer Survivors

This pilot clinical trial studies protein-sparing modified fast (PSMF) intervention for weight loss in obese endometrial cancer survivors. The PSMF is a diet that is very low in carbohydrates and calories, designed to induce fast, safe weight loss. The diet consists of only lean meats (beef, pork, poultry, and seafood) in amounts adequate to meet protein requirements based on the individual's body weight. The PSMF may help endometrial cancer survivors achieve significant weight loss, reduce the risk of chronic disease, and improve quality of life.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–70 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Cleveland Medical Center, University Hospitals, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Loading trial locations.

About this study

PRIMARY OBJECTIVES:

I. Investigate whether the PSMF leads to significant weight loss in obese endometrial cancer survivors (ECS).

II. To assess whether the approach is feasible, whether participants will remain in the study for the duration of the intervention while adhering to the various components of the protocol. To assess feasibility, examine the following variables: drop-out rates; rates of adherence to diet and supplemental protocol; and rates of common side-effects.

III. Assess whether the PSMF improves biomarkers of disease risk in this population. To assess whether this objective has been met, assess the following variables: blood lipids (total cholesterol, low density lipid [LDL] cholesterol, high density lipid [HDL] cholesterol, and triglycerides); glucose; and markers of inflammation (C-reactive protein, interleukin-6, tumor necrosis factor [TNF]-alpha, and leptin).

IV. Assess whether the PSMF leads to improvement in quality of life related to weight loss.

OUTLINE:

PSMF: Participants are instructed by a registered dietitian (RD) to consume enough lean beef, pork, poultry, and seafood to provide 1.2 grams of protein per kilogram of their obesity adjusted ideal body weight. The protein recommendation will be communicated to participants in terms of grams per day. Participants are encouraged to adhere as closely as possible to the protein recommendation. Based on the protein recommendation, participants are advised to consume a given amount (in ounces) of beef, pork, poultry and seafood daily, assuming that each ounce of these products contains seven grams of protein. Participants are provided with a digital kitchen scale to weigh protein-containing foods and are permitted up to 2 servings of non-starchy vegetables per day. Participants remain on the PSMF until they have successfully reduced their initial body weight by 15% or up to 6 months. Participants are also provided with supplements to consume daily.

WEIGHT MAINTENANCE DIET: After successful weight loss of at least 15% of initial body weight, participants are instructed by a RD to consume a weight maintenance diet or they may remain on the PSMF. The weight maintenance diet consists of gradual addition of previously eliminated carbohydrate containing food groups to the PSMF and consumption of non-starchy vegetables is unlimited. Participants receive handouts that list common foods and the number of carbohydrates in each serving and educated on nutrition label reading for carbohydrates, with emphasis on serving size and total number of carbohydrates per serving.

After completion of study, participants are followed up at 2 and 4 weeks and then at 2, 3, 4, 5, and 6 months.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Previous diagnosis of endometrial cancer, successfully treated through surgery
  • Body mass index (BMI) > 30 kg/m^2
  • > 8 weeks removed from surgery to treat endometrial cancer

Exclusion criteria

  • No previous diagnosis of endometrial cancer
  • BMI < 30 kg/m^2
  • Any history of cardiovascular, kidney, or liver disease
  • Using medication to treat diabetes
  • History of cardiac arrhythmias
  • Inability to comply with follow up regimen
  • Inability to read or speak English
  • Abstention from meat and other animal products

Treatment and study plan

dietary intervention

Dietary Supplement

Follow the Protein-Sparing Modified Fast (PSMF) intervention. This diet has participants consume enough lean beef, pork, poultry, and seafood to provide 1.2 grams of protein per kilogram of their obesity adjusted ideal body weight.

Other names: Dietary Modification, intervention, dietary

Informational Material

Other

Receive carbohydrate reintroduction handout

Dietary Education

Other

Receive education on nutrition label reading for carbohydrates

Other names: intervention, educational

Weight Maintenance

Dietary Supplement

weight maintenance diet consists of gradual addition of previously eliminated carbohydrate containing food groups to the high protein PSMF diet. During weight maintenance, consumption of non-starchy vegetables is unlimited

Average score of Obesity and Weight-Loss Quality of Life Questionnaire

Other

Participants will take a tailored quality of life questionnaire. These scores will be averaged and a group mean reported. Higher scores indicate greater quality of life.

Primary outcomes

  1. Mean Weight loss assessed with the digital scale

    Time frame: Baseline up to 6 months

    Mean weight loss will be presented as mean total weight loss in kilograms from baseline

  2. Mean Weight loss assessed with the digital scale

    Time frame: Baseline up to 12 months

    Mean Weight loss will be presented as mean total weight loss in kilograms from baseline.

Secondary outcomes

  1. Changes in levels of total cholesterol

    Time frame: Baseline up to 6 months

    Average differences in total cholesterol between time points will be assessed using a one-sided anova test with statistical significance defined as having a p-value < 0.05.

  2. Changes in levels of markers of inflammation (C-reactive protein)

    Time frame: Up to 6 months

    Average differences in C-reactive protein between time points will be assessed using a one-sided anova test with statistical significance defined as having a p-value < 0.05.

  3. Changes in levels of glucose

    Time frame: Up to 6 months

    Differences in glucose levels between time points will be assessed using a one-sided anova test with statistical significance defined as having a p-value < 0.05.

  4. Number of drop-out participants

    Time frame: Up to 6 months

    Presented as the difference in the number of participants who completed the study from the number of participants enrolled at baseline. This is reported as one of the markers of feasibility.

  5. Average percentage of positive urinary ketone tests as a marker of dietary adherence

    Time frame: Up to 6 months

    Assessed using the presence of urinary ketones beginning on day four of the intervention. Adherence rates will be presented as the percentage of positive urinary ketone tests for the duration of the intervention.

  6. Number of Participant with reported side effects

    Time frame: Up to 6 months

    Adverse events will be recorded by participants on a daily basis. Number of participants with related adverse events will be reported as one of the measures of feasibility

  7. Changes in quality-of-life as assessed by the Obesity and Weight Loss Quality-of-Life Questionnaire

    Time frame: Baseline up to 6 months

    The difference between mean quality of life scores at the two time points will be assessed using a one-sided anova test with statistical significance set at p < 0.05.

  8. Changes in levels of markers of inflammation (interleukin 6)

    Time frame: Up to 6 months

    Average differences in interleukin 6 between time points will be assessed using a one-sided anova test with statistical significance defined as having a p-value < 0.05.

  9. Changes in levels of markers of inflammation (tumor necrosis factor - alpha)

    Time frame: Up to 6 months

    Average differences in tumor necrosis factor - alpha between time points will be assessed using a one-sided anova test with statistical significance defined as having a p-value < 0.05.

  10. Changes in levels of markers of inflammation (leptin)

    Time frame: Up to 6 months

    Average differences of leptin between time points will be assessed using a one-sided anova test with statistical significance defined as having a p-value < 0.05.

  11. Changes in levels of LDL-cholesterol

    Time frame: Baseline up to 6 months

    Average differences between time points for LDL-cholesterol will be assessed using a one-sided anova test with statistical significance defined as having a p-value < 0.05.

  12. Changes in levels of HDL-cholesterol

    Time frame: Baseline up to 6 months

    Average differences between time points for HDL-cholesterol will be assessed using a one-sided anova test with statistical significance defined as having a p-value < 0.05.

  13. Changes in levels of triglycerides

    Time frame: Baseline up to 6 months

    Average differences between time points for triglycerides will be assessed using a one-sided anova test with statistical significance defined as having a p-value < 0.05.

Sponsors and collaborators

Lead sponsor

Case Comprehensive Cancer Center

Other

Collaborators

  • National Cancer Institute (NCI)

Registry information

Official study title

A Pilot Study of a Protein-Sparing Modified Fast for Weight Loss in Obese Endometrial Cancer Survivors

Important dates

Study start
2014
Primary completion
2017
Study completion
2017
First posted
May 12, 2014
Registry last updated
Sep 20, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.